Pipeline

We have a broad and differentiated pipeline of investigational drugs across our family of companies.

Cellular Background

10

positive Phase 3 trials since 2019

We have run numerous large successful international Phase 3 clinical trials.

Agnostic to therapeutic area and modality

Our pipeline includes innovative product candidates across numerous therapeutic areas.

Biologic · Immunovant
IMVT-1402
Graves' Disease
Registrational
Biologic · Immunovant
IMVT-1402
Difficult-to-Treat Rheumatoid Arthritis
Registrational
Biologic · Immunovant
IMVT-1402
Myasthenia Gravis
Registrational
Biologic · Immunovant
IMVT-1402
Chronic Inflammatory Demyelinating Polyneuropathy
Registrational
Biologic · Immunovant
IMVT-1402
Indication 5
Registrational
Biologic · Immunovant
IMVT-1402
Indication 6
Registrational
Biologic · Immunovant
Batoclimab
Thyroid Eye Disease
Registrational
Small Molecule · Priovant
Brepocitinib
Dermatomyositis
Registrational
Small Molecule · Priovant
Brepocitinib
Non-Infectious Uveitis
Registrational
Small Molecule · Priovant
Brepocitinib
Cutaneous Sarcoidosis
Proof of Concept
Inhaled · Pulmovant
Mosliciguat
Pulmonary Hypertension associated with Interstitial Lung Disease
Proof of Concept
video section decoration

Roivant CEO Matt Gline's presentation at the 2025 J.P. Morgan Healthcare Conference